- ►jcojournal.org JR Berenson, BE Hillner, RA Kyle, K Anderson … - Journal of Clinical Oncology, 2002 - jcojournal.org METHODS: An expert multidisciplinary Panel reviewed pertinent information from
the published literature through January 2002. Values for levels of evidence and
grade of recommendation were assigned by expert reviewers and approved by ... Cited by 253 - Related articles - BL Direct - All 10 versions
- ►physiology.org JE Compston - Physiological reviews, 2001 - Am Physiological Soc Compston, Juliet E. Sex Steroids and Bone. Physiol. Rev. 81: 419-447, 2001. Sex
steroids are essential for skeletal development and the maintenance of bone
health throughout adult life, and estrogen deficiency at menopause is a ... Cited by 246 - Related articles - BL Direct - All 5 versions
- ►ascopubs.org [PDF] EP Winer, C Hudis, HJ Burstein, RT … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org Purpose: To determine clinical practice guidelines for the use of
bisphosphonates in the prevention and treatment of lytic bone disease in
multiple myeloma and to determine their respective role relative to other ... Cited by 167 - Related articles - BL Direct - All 7 versions
- ►jcojournal.org J Pfeilschifter, IJ Diel - Journal of Clinical Oncology, 2000 - jcojournal.org ABSTRACT: Many therapeutic regimens in cancer treatment carry the risk of
causing or favoring the development of osteoporosis. Therapies in which
hypogonadism may occur are most relevant in this respect. Prompt hormone ... Cited by 155 - Related articles - BL Direct - All 7 versions
D Schrag, KM Kuntz, JE Garber, JC Weeks - Jama, 2000 - Am Med Assoc Context Women with BRCA1- or BRCA2-associated breast cancer are at increased
risk for contralateral breast cancer and ovarian cancer and therefore may
consider secondary cancer prevention strategies, such as prophylactic ... Cited by 149 - Related articles - All 4 versions
- ►ascopubs.org RT Chlebowski, DE Collyar, MR Somerfield, … - Journal of Clinical Oncology, 1999 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
From the American Society of Clinical Oncology, Alexandria, VA. Cited by 142 - Related articles - BL Direct - All 6 versions
- ►ascopubs.org RT Chlebowski, N Col, EP Winer, DE Collyar, … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
From the American Society of Clinical Oncology, Alexandria, VA. Cited by 137 - Related articles - BL Direct - All 6 versions
- ►pnas.org J An, RCJ Ribeiro, P Webb, JÅ Gustafsson, … - Proceedings of the National Academy of Sciences, 1999 - National Acad Sciences The tumor necrosis factor-α (TNF-α) promoter was used to explore the molecular
mechanisms of estradiol (E 2 )-dependent repression of gene transcription. E 2
inhibited basal activity and abolished TNF-α activation of the TNF-α ... Cited by 131 - Related articles - BL Direct - All 6 versions
SR Goldstein, WH Scheele, SK Rajagopalan, … - Obstetrics & Gynecology, 2000 - journals.lww.com Department of Obstetrics and Gynecology, New York University School of Medicine,
New York, New York; Lilly Research Laboratories, Eli Lilly and Company,
Indianapolis, Indiana; the Department of Obstetrics and Gynecology, Brigham ... Cited by 121 - Related articles - BL Direct - All 5 versions
- ►endojournals.org KM Prestwood, M Gunness, DB Muchmore, Y … - Journal of Clinical Endocrinology & Metabolism, 2000 - Endocrine Soc Raloxifene HCl, a selective estrogen receptor modulator, has been shown to
increase bone mineral density (BMD) and decrease biochemical markers of bone
turnover in postmenopausal women without stimulatory effects on the breast ... Cited by 119 - Related articles - BL Direct - All 6 versions
